Zenas BioPharma, Inc. (NASDAQ:ZBIO – Get Free Report) Director Jason Raleigh Nunn bought 63,158 shares of the stock in a transaction dated Thursday, October 9th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $1,200,002.00. Following the acquisition, the director owned 1,173,395 shares in the company, valued at $22,294,505. The trade was a 5.69% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Zenas BioPharma Stock Up 4.4%
Shares of NASDAQ ZBIO opened at $26.99 on Thursday. The firm’s 50-day simple moving average is $19.48 and its 200 day simple moving average is $13.74. The company has a market cap of $1.14 billion and a price-to-earnings ratio of -7.60. Zenas BioPharma, Inc. has a 12-month low of $5.83 and a 12-month high of $29.73.
Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.23).
Institutional Trading of Zenas BioPharma
Wall Street Analyst Weigh In
ZBIO has been the topic of several research reports. Wedbush upped their price target on shares of Zenas BioPharma from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Zenas BioPharma in a research report on Thursday, October 9th. Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Friday, September 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.33.
Read Our Latest Report on ZBIO
Zenas BioPharma Company Profile
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
- Five stocks we like better than Zenas BioPharma
- What is Insider Trading? What You Can Learn from Insider Trading
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Buy P&G Now, Before It Sets A New All-Time High
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Earnings Per Share Calculator: How to Calculate EPS
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.